News | May 29, 2024
Lilly increases manufacturing investment to US$ 9 billion at newest Indiana site
Largest investment in active pharmaceutical ingredient manufacturing of synthetic medicines in U.S. history
Largest investment in active pharmaceutical ingredient manufacturing of synthetic medicines in U.S. history
EBITDA before special items falls 1.3 percent to € 4.41 billion
The company has posted net profit) of Rs.18.88 crores for the Financial Year ended March 31, 2024
These facilities are commissioned by Aurobindo's wholly own subsidiary: Lyfius Pharma Private Limited, Qule Pharma Private Limited, Eugia Steriles Private Limited and Auroactive Pharma Private Limited.
This partnership marks a significant step for the Company towards establishing renewable energy power generation using hybrid open excess through solar and wind sources
The disbursement will bolster the company's manufactun'ng capabjljties and foster product diversification, including complex generics
Cipla completes transfer of Generics Business Undertaking
Sustainability is integral to Biocon's business purpose
This recognition attests to Sun Pharma’s commitment to incorporate Environmental, Social, and Governance (ESG) principles through focused initiatives across its businesses
The launch will enable PCC to further expand their existing Zinc Sulfate Injection product line and overall the generic injectables portfolio
Subscribe To Our Newsletter & Stay Updated
